At Abvion, we source antibodies directly from the serum of individuals with exceptional immune responses.  This includes elite responders with superior disease recovery and people producing other valuable antibodies. Such antibodies represent serological prototypes: highly effective, well-tolerated molecules ideal as starting points for therapeutics.

​

Our protein-level discovery approach captures these valuable antibodies directly from biofluids, including archived biobank materials. It delivers fully mature, in vivo optimized antibodies, the functional molecules themselves, which are inaccessible to single-cell NGS approaches.  This enables faster, more precise development of therapies with superior efficacy and safety, setting a new standard in human-derived antibody therapies.